Fundraising Fox
Therivabio
Rockville, US · 18 employees on LinkedIn · 1 known investors
Find your way into Therivabio
Each arrow is one introduction. Sign up to fill in the first one.
Ask Eva Mendez Camarena to introduce you to Steven A. Shallcross
You →Eva · together at Therivabio →Steven
Sign up to find every way you can get introduced to Therivabio
- Your email: who you already know at Therivabio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Therivabio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Theriva Biologics is a clinical-stage company developing therapeutics for cancer and related diseases, including an oncolytic adenovirus platform (VCN-01) and enzyme-based candidates for gastrointestinal and systemic conditions (SYN-004, SYN-020). It is a publicly traded biopharmaceutical company (NYSE American: TOVX) focused on areas of high unmet medical need.
Founders & leadership
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$29.6M disclosed across 4 rounds · 2017–2025
▶$13.1MraisedOct 2025 · 10 investors · BiotechnologyRule 506(b)
- Jeffrey J. KrawsDirector
- Jeffrey A. WolfDirector
- John MonahanDirector
- Steven A. ShallcrossExecutive Officer, Director
- Offering amount
- $13.1M
- Amount sold
- $13.1M
- Sales commissions
- $308K
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Oct 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3MraisedAug 2022 · 1 investors · BiotechnologyRule 506(b)
- Jeffrey WolfDirector
- Jeffrey J. KrawsDirector
- John MonahanDirector
- Steven A. ShallcrossExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- Minimum investment
- $3M
- Finders' fees
- $175K
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Jul 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.5MraisedMar 2022 · 4 investors · BiotechnologyRule 506(b)
- Steven A ShallcrossExecutive Officer, Director
- Jeffrey J. KrawsDirector
- John MonahanDirector
- Jeffrey WolfDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Mar 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$12MraisedSep 2017 · 1 investors · BiotechnologyRule 506(b)
- Scott TarriffDirector
- Jeffrey KrawsDirector
- Joseph SlimanExecutive Officer
- Jeffrey WolfDirector
- Steven ShallcrossExecutive Officer
- Jeffrey RileyExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $12M
- Minimum investment
- $12M
- First sale
- Sep 2017
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Therivabio.
Frequently asked questions
- What does Therivabio do?
- Theriva Biologics is a clinical-stage company developing therapeutics for cancer and related diseases, including an oncolytic adenovirus platform (VCN-01) and enzyme-based candidates for gastrointestinal and systemic conditions (SYN-004, SYN-020). It is a publicly traded biopharmaceutical company (NYSE American: TOVX) focused on areas of high unmet medical need.
- Who are Therivabio's investors?
- Therivabio's investors include Kinled Holding.
- How much funding has Therivabio raised?
- Therivabio has disclosed $29.6M raised across 4 rounds.
- Where is Therivabio headquartered?
- Therivabio is headquartered in Rockville, US.